Arthneeti

Gujarat Kidney & Super Speciality Share Price & Earnings Call Analysis

₹161.05-1.55% today
Market cap
₹1,270 Cr
P/E
80.21
ROE
11.14%
PEG
0.08
Price to sales
12.56
Debt to equity
0.12
52W high / low
₹195 / ₹99.4
EBITDA margin
26.41%
Net profit margin
20.52%
Promoter holding
71.45%
Sales (last year)
₹101 Cr

Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM Quality Care LtdGood growth
    3
See all potential multibaggersWhere does Gujarat Kidney rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹921 Cr—
240%+Flat₹575 Cr21.9
3Aster DM Quality Care Ltd20–40%Up 2%+₹59,405 Cr164.6
420–40%Up 2%+₹551 Cr18.5
520–40%Up 0–2%₹1,635 Cr16.5
620–40%Flat₹1.21L Cr57.7

Sign up free to see every company in the sector ranking and track Gujarat Kidney.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Financials of Gujarat Kidney

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Gujarat Kidney

Quarterly Results

Quarter-by-quarter operating performance

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +9.4111.799.7815.2612.9323.2530.58
Expenses +4.557.197.176.647.8116.3524.28
Operating Profit4.864.602.618.625.126.906.30
OPM %51.65%39.02%26.69%56.49%39.60%29.68%20.60%
Other Income +0.040.050.050.010.090.060.71
Interest0.160.170.160.180.280.600.82
Depreciation0.740.880.900.960.901.331.51
Profit before tax4.003.601.607.494.035.034.68
Tax %26.25%29.72%16.88%27.77%28.54%26.44%-2.99%
Net Profit +2.962.531.345.402.883.704.82
EPS in Rs18.3915.530.230.850.470.370.64

Financials of Gujarat Kidney

Profit & Loss

Annual income statement trend

Mar 2023Mar 2024Mar 2025Mar 2026
Sales +054082
Expenses +032455
Operating Profit-021727
OPM %41%41%33%
Other Income +0101
Interest0012
Depreciation0035
Profit before tax-021321
Tax %0%25%26%21%
Net Profit +-021017
EPS in Rs-0.5085.501.661.97
Dividend Payout %0%0%0%0%

Financials of Gujarat Kidney

Balance Sheet

Capital structure and asset base

Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.200.201116
Reserves01115237
Borrowings +06829
Other Liabilities +442116
Total Liabilities42155298
Fixed Assets +01431129
CWIP0000
Investments0000
Other Assets +4724169
Total Assets42155298

Financials of Gujarat Kidney

Cash Flows

Operating, investing and financing cash movement

Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +0114
Cash from Investing Activity +00-18
Cash from Financing Activity +0-06
Net Cash Flow012
Free Cash Flow02-5
CFO/OP0%70%99%

Financials of Gujarat Kidney

Ratios

Working capital efficiency and return ratios

Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days321138172
Inventory Days82
Days Payable339
Cash Conversion Cycle321138-84
Working Capital Days100-2491
ROCE %19%52%14%

Continue your research

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q2 FY27)

    Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves

  • Shalby (Q2 FY27)

    Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S

  • Metropolis Healt (Q2 FY27)

    Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre

  • Nephrocare Health Services (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Key investor presentation takeaways from Nephrocare Health Services

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health